

1 **Evolutionary and phenotypic characterization of spike**
2 **mutations in a new SARS-CoV-2 Lineage reveals two**
3 **Variants of Interest**

4 Paula Ruiz-Rodriguez^{1#}, Clara Francés-Gómez^{1#}, Álvaro Chiner-Oms², Mariana G. López²,
5 Santiago Jiménez-Serrano², Irving Cancino-Muñoz², Paula Ruiz-Hueso³, Manuela Torres-Puente²,
6 Maria Alma Bracho^{1,4}, Giuseppe D’Auria^{1,3,4}, Llúcia Martínez-Priego³, Manuel Guerreiro^{5,6}, Marta
7 Montero-Alonso⁷, María Dolores Gómez⁸, José Luis Piñana⁹, SeqCOVID-SPAIN consortium,
8 Fernando González-Candelas^{1,4}, Iñaki Comas^{2,4}, Alberto Marina^{2,10}, Ron Geller^{1*}, Mireia
9 Coscolla^{1*}

10 1. ¹SysBio, University of Valencia-CSIC, FISABIO Joint Research Unit Infection and Public Health,
11 Valencia, Spain.

12 2. Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.

13 3. Sequencing and Bioinformatics Service of FISABIO (Valencian Region Foundation for the
14 Promotion of Health and Biomedical Research), Valencia, Spain.

15 4. CIBER in Epidemiology and Public Health, Spain.

16 5. Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain

17 6. Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain.

18 7. Infectious Diseases Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

19 8. Microbiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

20 9. Hematology Service, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia,
21 Spain.

22 10. CIBER in Rare Diseases (CIBERER), Spain.

23 #equal contributions

24 *corresponding author

25 **Keywords:** SARS-CoV-2, Spike, HR2, variants, homoplasy, and antibody escape.

26 **Abstract**

27 Molecular epidemiology of SARS-CoV-2 aims to monitor the appearance of new variants with
28 the potential to change the virulence or transmissibility of the virus. During the first year of
29 SARS-CoV-2 evolution, numerous variants with possible public health impact have emerged. We
30 have detected two mutations in the Spike protein at amino acid positions 1163 and 1167 that
31 have appeared independently multiple times in different genetic backgrounds, indicating they
32 may increase viral fitness. Interestingly, the majority of these sequences appear in transmission
33 clusters, with the genotype encoding mutations at both positions increasing in frequency more
34 than single-site mutants. This genetic outcome that we denote as Lineage B.1.177.637, belongs
35 to clade 20E and includes 12 additional single nucleotide polymorphisms but no deletions with
36 respect to the reference genome (first sequence in Wuhan). B.1.177.637 appeared after the first
37 wave of the epidemic in Spain, and subsequently spread to eight additional countries, increasing
38 in frequency among sequences in public databases. Positions 1163 and 1167 of the Spike protein
39 are situated in the HR2 domain, which is implicated in the fusion of the host and viral
40 membranes. To better understand the effect of these mutations on the virus, we examined
41 whether B.1.177.637 altered infectivity, thermal stability, or antibody sensitivity. Unexpectedly,
42 we observed reduced infectivity of this variant relative to the ancestral 20E variant *in vitro* while
43 the levels of viral RNA in nasopharyngeal swabs did not vary significantly. In addition, we found
44 the mutations do not impact thermal stability or antibody susceptibility in vaccinated individuals
45 but display a moderate reduction in sensitivity to neutralization by convalescent sera from early

46 stages of the pandemic. Altogether, this lineage could be considered a Variant of Interest (VOI),
47 we denote VOI1163.7. Finally, we detected a sub-cluster of sequences within VOI1163.7 that
48 have acquired two additional changes previously associated with antibody escape and it could
49 be identified as VOI1163.7.V2. Overall, we have detected the spread of a new Spike variant that
50 may be advantageous to the virus and whose continuous transmission poses risks by the
51 acquisition of additional mutations that could affect pre-existing immunity.

52 **Introduction**

53 Genomic surveillance of viral mutations is the first step in detecting viral changes that could
54 impact public health by interfering with diagnostics, modifying pathogenicity, or altering
55 susceptibility to existing immunity or treatments. In many countries, the challenge of detecting
56 new mutations of interest in SARS-CoV-2 is approached by sequencing representative genomes
57 from circulating viruses, sharing sequence information on public databases (e.g. GISAID¹), and
58 analysing them in real-time using platforms, such as Nextstrain². While mutations appear
59 randomly, their fate in the population depends on a combination of the conferred fitness
60 advantage as well as stochastic and demographic processes. A first step in assessing the
61 potential public health impact of mutations is to decipher if their increase in frequency is due to
62 chance or adaptation. If found to be adaptive, it is important to evaluate whether their
63 adaptation is linked to an improved ability to replicate, colonize, transmit, or evade antiviral
64 hosts defences³. An important challenge in the field is to decipher which of all the variants that
65 appear should be monitored to implement measures to mitigate their risk to public health.
66 Genotypes that are phenotypically different from a reference isolate or have mutations that lead
67 to changes associated with either established or suspected phenotypes could be considered
68 Variants of Interest (VOI) if they also fit one of the following criteria: i) cause community
69 transmission/multiple COVID-19 clusters or ii) have been detected in multiple countries⁴. Among
70 VOI, only those genotypes that are associated with higher transmissibility, with detrimental

71 changes in COVID-19 epidemiology, with increased virulence, with changes to clinical
72 presentation, or with decrease effectiveness of public health measures, diagnostics, vaccines or
73 therapeutics are further categorized as variants of concern⁴.

74 Mutations in SARS-CoV-2 have been reported since the early stages of the epidemic⁵⁻⁷. While no
75 signs of recombination have been detected so far among SARS-CoV-2 variants⁸, the most
76 common mutations described are single nucleotide polymorphisms (SNPs) and small deletions⁹⁻
77 ¹¹. Genomic surveillance of mutations has been mostly focused on the Spike (S) protein because
78 of its key roles in viral entry and immunity¹², as well as the fact that this protein constitutes the
79 basis of numerous SARS-CoV-2 vaccines¹³. S is a homotrimeric protein, whose heavily
80 glycosylated ectodomain protrudes from the viral membrane, showing a bat-like shape with a
81 N-terminal globular head portion connected to the membrane by an elongated stalk¹⁴. The S
82 protein is proteolytically processed by the cellular furin protease into the S1 and S2 subunits^{15,16}.
83 Additional proteolytic cleavage occurs following S protein binding to the host receptors,
84 facilitating S1 subunit release. The C-terminal S2 subunit remains trimeric in the viral membrane
85 but undergoes conformational changes that promote viral membrane fusion with the host cell¹⁷.
86 A key role in these conformational changes is played by two heptad repeat motifs, HR1 and HR2
87 that, starting from the head and stalk regions in the pre-fusion state of S protein, form a HR1-
88 HR2 six-helix bundle in the post-fusion state that is critical for viral entry¹⁸.

89 The first mutation that was identified as of potential concern was an aspartic acid to a glycine
90 mutation in the S1 subunit of the S protein at position 614 (D614G). D614G emerged early in the
91 epidemic, became predominant in most countries within 2 months, and completely dominated
92 the epidemic by August 2020¹⁹. As with any mutant, the initial spread of this mutation could
93 have resulted from stochastic events, the dynamics of epidemic, or an intrinsically higher viral
94 fitness. More than six months after the initial report of this mutation, several studies have found
95 evidence in favour of higher transmission efficacy in animal models and human populations^{5,20-}

96 ²². This variant replicates better in some cell culture and animal models^{20,21,23}, and is associated
97 with higher viral loads in infected individuals¹⁹; importantly, however, it does not impact
98 diagnostics or vaccine efficacy.

99 Following the first wave of the pandemic, additional variants have been reported from many
100 countries. Among the first of these was the A222V mutation at the N-terminal domain (NTD) of
101 the S1 subunit, which occurred in the background of the D614G S protein mutation. This variant,
102 termed 20E, was first sequenced in Spain and expanded throughout Europe⁶. Other variants
103 have been reported since, such as the so-called “cluster 5”, which harbours a combination of 3
104 SNPs and single deletion related to mink farms in Denmark²⁴. One of the SNPs is in the S protein
105 of this variant, Y453F, occurs in the receptor binding domain (RBD) and may increase binding to
106 cell receptors in mink²⁵. Transmission of this variant between humans and minks has been
107 reported⁷, highlighting a possible risk of expansion in the human population, which resulted in
108 proposals for large scale culling of mink populations in Denmark. Studies to assess the biological
109 impact of this mutant have not been reported but there is no evidence for its wide spread over
110 the course of >6 months since its description²⁶. By December 2020, three variants of concern
111 (VOCs) were described, all of which share the N501Y amino acid replacement in the RBD of the
112 S protein: 20I/501Y.V1 (also called Lineage B.1.1.7) was originally described in the UK¹¹,
113 20H/501Y.V2 (B.1.351) in South Africa, and 20J/501Y.V3 (P1) in Brazil. These variants are of
114 particular concern because they are more transmissible²⁷⁻²⁹ and, although data on antigenicity
115 and disease severity is not conclusive, could result in reduced susceptibility to neutralization by
116 existing immunity and affect vaccine efficacy³⁰⁻³³. Importantly, all of these variants have spread
117 outside of the country where they were initially identified and are estimated to spread faster
118 than other co-circulating genotypes^{27,34,35}.

119 In this work, we have performed a detailed phylogenomic analysis of the appearance, spread
120 and evolution of two mutations involving amino acid positions 1163 and 1167 of the HR2

121 functional motif of S protein. Our results provide evidence of repeated, independent
122 emergence, suggesting these mutations contribute to increased viral fitness. In addition, we
123 have evaluated the biological relevance of these mutations to viral infectivity, virion stability,
124 and neutralization by sera from convalescent and vaccinated individuals.


125 **Results**

126 **Multiple and independent mutations in amino acid positions 1163 and 1167 of the Spike** 127 **protein.**

128 SARS-CoV-2 genetic variation has been monitored by the Spanish sequencing consortium
129 SeqCOVID to follow the expansion of mutations that could potentially result in a change of the
130 biological properties of the virus. We focused on mutations in the S protein because of its
131 relevance for infection and immunity¹². We detected two mutations in the *spike* gene: G25049T
132 (D1163Y) and G25062T (G1167V), which appeared in Spain as early as March and April 2020,
133 respectively (Supplementary Fig.1). These mutations continued arising independently of each
134 other and, by the end of June, when the predominant circulating genotypes from the first wave
135 in Spain had already been replaced by other variants³⁶, were also observed together
136 (Supplementary Fig.1). Both positions have mutated multiple times independently and to
137 different amino acids at a lower frequency. On the one hand, D1163 appears mutated at least
138 99 times (D1163Y: 84, D1163V: 4, D1163G: 3, D1163A: 2, D1163E: 2, D1163H: 2, D1163N: 1, and
139 D1163H/Y: 1) in 47 lineages according to the PANGO scheme³⁷. On the other hand, G1167
140 appears mutated at least 54 times (G1167V: 39, G1167D: 4, G1167C: 3, G1167R: 3, G1167S: 3,
141 G1167F: 1, and G1167A: 1) in 20 PANGO lineages including B.1 (Supplementary Fig.2e) and its
142 derivatives B.26, B.40 (Supplementary Fig.2c), and D.2 (Supplementary Fig.2f).

143 **Clusters of transmission with amino acid changes in positions 1163 and 1167 of Spike**

144 Positions 1163 and 1167 in the S protein have mutated independently multiple times in SARS-
145 CoV-2. The majority of mutated sequences (94.43%) were found in transmission clusters (see
146 methods for definition of clusters; Figure 1a,b), with a small minority not belonging to a
147 transmission cluster due to either incomplete sampling or failure to spread. While different
148 amino acids changes have been detected at both positions, only one change at each position
149 appeared in most clusters: D1163Y in 83.33% and G1167V in 69.23% clusters. D1163Y appeared
150 in 22 transmission clusters (Figure 1a) and G1167V in 8 clusters (Figure 1b). Interestingly, the
151 biggest cluster included both the D1163Y and G1167V mutations together. We denote this
152 cluster as B.1.177.637, which was detected in 65 sequences from Spain until December 2020,
153 representing 1.17% of the Spanish sequences. Globally, this cluster, which is within lineage 20E
154 (also described as 20A.EU1⁶, and B.1.177³⁷), includes 1,627 sequences (Figure 1c). B.1.177.637
155 is characterized by nine nonsynonymous and six synonymous mutations with respect to the
156 reference sequence from Wuhan (Supplementary table 2), but no deletions were shared among
157 B.1.177.637 sequences. Amino acid changes were found in A222V, D614G, D1163Y, and G1167V
158 in the S protein, A220V and P365S in the N protein, V30L in ORF10, L67F in ORF14, and P4715L
159 in ORF1ab (Supplementary Fig.3 and Supplementary table 2). Synonymous mutations were also
160 observed in the *orf1ab*, *n* and *m* genes (Supplementary Fig.3 and Supplementary table 2). All
161 evidence support we consider this cluster a new Lineage, and we requested to be under the
162 name B.1.177.637 (<https://github.com/cov-lineages/pango-designation/issues/22>).



163

164 **Figure 1. Sequences mutated at positions 1163 and 1167 of the S protein.** a. The number of
 165 mutation events for amino acid replacement D1163Y (light orange) or another D1163 amino acid
 166 replacements (dark orange). b. The number of mutation events for amino acid replacement
 167 G1167V (light turquoise) or another G1167 amino acid replacements (dark turquoise). Bars
 168 coloured in magenta indicate the appearance of both the D1163Y and G1167V amino acid
 169 replacements in the same sequences. c. Maximum-likelihood phylogeny of 10,450 SARS-CoV-2
 170 genomes. The inner circle of the rings represents sequences with amino acid changes in position
 171 D1163 of the S protein. The external circle represents sequences with amino acid changes in
 172 position G1167 of the S protein. Branches are coloured in magenta for B.1.177.637, green for
 173 clade 20E, and orange for cluster 1163.654. The scale bar indicates the number of nucleotide
 174 substitutions per site. d. Temporal distribution and frequency of sequences with variant
 175 B.1.177.637 coloured by geographical origin.

176 Within 20E, the second largest cluster including any of these mutations was observed in 34
 177 sequences with E654Q and D1163Y in S protein plus 7 nonsynonymous and 6 synonymous
 178 mutations (Supplementary table 2 and Supplementary Fig.3). We denote this second cluster,
 179 which is also embedded within lineage 20E, cluster 1163.654 (Figures 1c and S3). Cluster
 180 1163.654 appeared first in Ireland on 2020-07-23 and subsequently appeared in Spain and

181 England. However, after three months, cluster 1163.654 is no longer being detected. A large
182 cluster within Lineage 20E is formed by 37 sequences with the mutation G1167F. Sequences for
183 this cluster were obtained in Wales between the end of October and the beginning of November
184 2020 (dark pink in the external circle in Supplementary Fig.2g).

185

186 We found additional clusters involving mutations in position 1163 of the S protein; the largest
187 cluster is composed of 64 sequences within Lineage B.1. The majority of which are from
188 Denmark but also includes sequences from England and Sweden (orange in external ring in
189 Supplementary Fig.2e). Among other smaller clusters, a cluster of 10 sequences with G1167V
190 (within Lineage B.1) appeared in Spain in March (indicated in cyan within the external circle of
191 Supplementary Fig.2e). The cluster was detected in two regions in Spain (Valencia, and Galicia),
192 but was controlled with lockdown measures imposed in Spain from March to May and was not
193 detected after May 2020. The same mutation was found in a cluster of 28 sequences within 20E
194 from England and Wales between October and November 2020 (indicated in cyan within the
195 external circle of Supplementary Fig.2g). Similarly, another cluster of 11 sequences in Lineage
196 B.1.1 and with the mutation G1167A was detected in early January 2021, encompassing
197 sequences from Ecuador, Colombia, and Peru (Supplementary Fig.2f). Within Lineage B.53, we
198 found a cluster of 12 sequences from Lithuania with mutation D1163Y. Finally, we found small
199 clusters with mutations in 1163 or 1167 within Lineage B.40 and Lineage A (Supplementary
200 Fig.2b, c).

201 Because of the risk posed by VOC^{11,26,35}, we examined whether mutations in 1163 and 1167 of
202 the S protein were observed in the three VOC described to date. Indeed, mutations in these two
203 positions were observed in two VOC, 20I/501Y.V1 and 20H/501Y.V2. Mutations involving amino
204 acid positions 1163 and 1167 appeared independently in the background of 20I/501Y.V1
205 multiple times. Specifically, mutations in D1163 have occurred at least 13 times in 24 sequences,

206 including four transmission clusters and nine unique sequences (Supplementary Fig.4), while
207 mutations at G1167 were observed in at least five independent sequences. Interestingly,
208 D1163Y and G1167V were observed together in only one individual within 20I/501Y.V1,
209 although they were not fixed (relative frequency of 27% and 17% of the reads with D1163Y and
210 G1167V, respectively; Supplementary table 3). Finally, only two sequences that harbour the
211 amino acid replacement G1167V in the S protein were observed in the genomic background
212 20H/501Y.V2 (Supplementary table 3).

213 **Evolution of B.1.177.637**

214 We explored the emergence and evolution of B.1.177.637, the largest and most successful
215 cluster involving amino acid changes in positions 1163 and 1167 of the S protein. Lineage
216 B.1.177.637 appeared in Spain in June 2020 in sequences from the Basque Country (Figure 1d,
217 and Supplementary Video 1) and subsequently appeared in individuals from other countries,
218 comprising a total of 1,627 sequences in GISAID (0.60% of 270,869 analysed sequences by 23rd
219 of December 2020) (Figure 1d and Supplementary Video 1). The majority of the B.1.177.637
220 sequences were obtained from the United Kingdom, including England (1,058), Scotland (419),
221 Wales (34) and Northern Ireland (5), but were also observed in Gibraltar (24 sequences),
222 indicating successful migration and transmission (Supplementary Video 1). Although
223 B.1.177.637 is not well represented in sequences from other countries, it has been found in
224 multiple sequences from Denmark (9), Switzerland (8), Norway (2), and single sequences from
225 Italy, France, Singapore, and Ireland. By the end of 2020, B.1.177.637 was still circulating in
226 Europe (Figure 1d and Supplementary Video 1), and by the end of February 2021 it was
227 represented by 1,923 sequences in GISAID (0.33% of submitted sequences).

228 Within B.1.177.637, we detected additional SNPs in individual sequences or small groups of
229 sequences. One of these changes is E484K in the RDB of the S protein, a mutation present in
230 three VOCs (20I/501Y.V1, 20H/501Y.V2 and 20J/501Y.V3) that is implicated in increased ACE2


231 binding³⁸ and reduced neutralization by antibodies³⁹. In addition, we found another change
232 associated with evasion of antibody immunity: a deletion of positions 141-144 in the S protein,
233 which partially overlaps with a smaller deletion at 144 reported in VOC 20I/501Y.V1⁴⁰. This sub-
234 cluster included five sequences along January 2021 from England and Wales (Supplementary
235 table 2). The five sequences formed a monophyletic group embedded in B.1.177.637
236 (Supplementary Fig.5), identified as cluster B.1.177.637.V2, which displays other
237 nonsynonymous and synonymous mutations (Supplementary table 2) and only two sites are
238 polymorphic within B.1.177.637.V2.

239 **Positions 1163 and 1167 of the S protein are located in the heptad repeat 2 motif**

240 The S protein mediates both the binding to cellular receptors and entry into the host cells¹². For
241 the former, the RBD motif in the S1 subunit interacts with the cellular receptor in the pre-fusion
242 state. In the post-fusion state, two heptads repeat sequences (HR1 and HR2) in the S2 subunit
243 must form a six-helix bundle in order to bring the viral and cellular membrane into close
244 proximity^{41,42} (Figure 2). S protein positions 1163 and 1167 are both located within the HR2
245 domain. Specifically, 1167 is present at the beginning of the HR2 motif and 1163 in its upstream
246 linker region (Figure 2a). Interestingly, this motif is highly invariable, showing 100% conservation
247 across 14 related sarbecoviruses to which SARS-CoV-2 belongs to (Supplementary table 1)^{43,44}.
248 Structural characterization of full-length ectodomain of S protein has shown that the stalk
249 portion encompassing positions 1163 and 1167 presents intrinsic flexibility in the pre-fusion
250 state¹⁸, precluding its atomic visualization. This has been recently confirmed by high-resolution
251 cryo-electron tomographic reconstitution of SARS-CoV-2¹⁴, where this region was observed to
252 constitute a flexible hinge that acts as a “knee”, connecting two helical coiled-coil regions of the
253 stalk (upper and lower legs; Figure 2b). Within this structure, the conformational freedom
254 provided by the glycine residue at position 1163 should play a key role in the flexibility of the
255 knee. In contrast, in the post-fusion state, this region shows high rigidity due to a strong

256 structural rearrangement of the HR2 motif, which adopts an extended conformation and tightly
257 packs along the central 3-helix bundle stem formed by the HR1 motif (Figure 2c). The resulting
258 HR1-HR2 bundle plays a key role in the mechanism of viral-host membrane fusion^{18,45} and
259 mutations in this region could have significant impact on the function of the S protein. In
260 addition, the HR2 region is highly glycosylated, which is observed to be regularly spaced in both
261 the pre- and post-fusion states and to mostly align to the side of the helix bundle^{14,18,45}. Of note,
262 two of these branched sugars are placed at positions N1158 and N1173, hiding positions 1163
263 and 1167 (Figure 2b). Therefore, changes in stalk flexibility might have relevance in immunity by
264 influencing both the intrinsic degree of exposure of this region and its sugar shielding.

265 Using the available structural information of the S protein in the pre- and post-fusion
266 conformations¹⁸, we examined the possible implications of these mutations to viral infectivity.
267 Based on these structures, G1167V mutation is predicted to confer significant rigidity to the
268 structure in two ways. First, the introduction of a side chain strongly reduces the conformational
269 freedom provided by the glycine residue. Second, the presence of the new aliphatic side chain
270 provided by the valine residue strongly increases hydrophobicity, likely promoting the burial of
271 this side chain in the HR1 helix 3-bundle stem in the post-fusion state or favouring its integration
272 in the neighbour helical coiled-coil in the pre-fusion state (Figure 2b,c). Unlike position 1163,
273 position 1167 is fully exposed to the solvent in both the pre- and post-fusion states (Figure 2b,c).
274 Hence, the effect of D1163Y is likely to stem a change in nature of the side chain, switching from
275 a charged aspartic acid residue at physiological pH to a polar group with hydrophobic properties
276 in the tyrosine.



277

278 **Figure 2. The structure of 1163 and 1167 in the pre and post-fusion states of S protein. a.**

279 Schematic representation of the S protein. SP, Signal peptide; NTD, N-terminal domain; RBD,
 280 receptor-binding domain; SD1-2, subdomains 1 and 2; L-UH, Linker-Upstream helix; FP, fusion
 281 peptide; CR, connecting region; HR1, heptad repeat 1; CH-SD3, central helix subdomain 3; BH,
 282 β -hairpin; HR2, heptad repeat 2; TM, transmembrane; CD, cytoplasmic domain. Mutations
 283 D1163Y and G1167V are indicated in purple and other mutations described in the text in green.


284 **b.** Cartoon representation (*left*) of a structural model of pre-fusion membrane-bound trimeric S
 285 protein⁴⁶. In each subunit the RBD, HR1 and HR2 domains are coloured in different tones (light
 286 to dark) of blue, yellow, and green. The N-glycosylation of N1155 and N1176 are shown in stick
 287 representation and coloured as the corresponding subunit. Functional and structural regions are
 288 marked. A close-view (*right*) of the N-terminal portion of HR2 where D1163Y and G1167V
 289 mutations are found. The side-chains of mutated and hydrophobic residues in the HR2 region
 290 are shown in stick representation and coloured as corresponding subunit (mutated residues in
 291 lighter tone). **c.** Cartoon representation (*left*) of S2 subunit in post-fusion conformation with HR1

292 and HR2 regions coloured as in b and N-glycosylation around mutation position shown as sticks.
293 A close-view of the region encompassing the mutations (right), showing in stick representation
294 the mutated and hydrophobic residues from the HR2 region shown in panel b. Dotted lines
295 highlight HR2 disordered regions in the Cryo-EM structure.

296 **Spike aminoacid changes D1163Y and G1167V do not increase viral infectivity**

297 Previous reports have indicated that mutations in the S protein can increase infectivity^{5,21,47-49}.
298 Because the highest transmission success for mutations in S positions 1163 and 1167
299 corresponds to the double mutant D1163Y and G1167V (characteristic of B.1.177.637), we
300 explored whether these mutations in combination have an influence on infectivity. For this, we
301 pseudotyped vesicular stomatitis virus lacking its glycoprotein and encoding GFP⁵⁰ (VSVΔG-GFP)
302 with different S genotypes: Wuhan (D614), D614G, 20E (A222V and D614G), or B.1.177.637
303 (A222V, D614G, D1163Y and G1167V). Infectious virus production was then assessed by limiting
304 dilution and counting of GFP-positive cells in both Vero cells and A549 human alveolar basal
305 epithelial cells expressing human ACE2 and TMPRSS2 (A549-hACE2-TMPRSS2). As previously
306 reported^{19,21,51}, the 20E S genotype enhanced infectivity relative to the Wuhan S genotype by
307 70% in both Vero (p-value = 0.005 by unpaired t-test; Figure 3a) and A549-hACE2-TMPRSS2 cells
308 (p-value = 0.016 by unpaired t-test; Figure 3b). The 20E S genotype also showed a trend towards
309 increased infectivity versus the D614G mutation alone (35% increase in both cell lines), as has
310 been previously reported⁴⁹, yet the difference was not statistically significant (p-value > 0.05 by
311 unpaired t-test; Figure 3a,b). In contrast, B.1.177.637 S genotype significantly diminished virus
312 infectivity versus the 20E genotype, reducing virus titers by 20% in Vero cells (p-value = 0.009 by
313 unpaired t-test; Figure 3a) and 29% in A549-hACE2-TMPRSS2 (p-value = 0.03 by unpaired t-test;
314 Figure 3b). This is in agreement with a potential stabilization of the HR2 helix (Figure 2), which
315 should limit the ability of the S protein to sample different structural conformations that could

316 be required for binding host-cell receptors. Hence, B.1.177.637 S genotype does not increase
317 infectivity *in vitro*.



318

319 **Figure 3. Comparison of the infectivity and stability of different S genotypes. a, b.** The
320 infectivity of VSV particles pseudotyped with each S protein genotype in either Vero (a) or
321 human A549 cells expressing ACE2 and TMPRSS2 (b). The mean and standard deviation of three
322 replicates is plotted. c. Comparison of cycle threshold (Ct) values for the *n* gene from patients
323 infected with viruses encoding different S protein variants. Data is derived from 2,534 sequences
324 from SeqCOVID consortium. The number of observations (N) analysed for each genotype is
325 indicated. d. The thermal sensitivity of VSV pseudotyped with different S genotypes following
326 incubation at 15 minutes. Data are standardized to the surviving fraction following incubation
327 at 30°C, and the three-parameter log-logistic equation is plotted. FFU: focus forming units.

328 To examine whether reduced infectivity could also be observed *in vivo*, we tested if individuals
329 infected with B.1.177.637 have different viral loads. For this, we used the cycle threshold (Ct) of
330 real-time PCR used for diagnosis as a surrogate. As previously reported¹⁹, we detected higher Ct
331 values for D614 wild-type variant (Ct mean = 27.00) compared to genotypes encoding the D614G
332 S protein mutation (Ct mean = 25.32; p-value < 0.01 by unpaired Wilcoxon test, Figure 3c).
333 However, we did not find significant differences in viral loads between individuals infected with
334 B.1.177.637 genotype and other genotypes within 20E (Ct mean = 21.14 vs Ct mean = 20.63, p-
335 value = 0.72 by unpaired Wilcoxon test, Figure 3c). Interestingly, higher viral loads were
336 observed in individuals infected with B.1.177.637 and others 20E (D614G and A222V) compared
337 to the D614G alone (D614G Ct mean = 25.32, 20E Ct mean = 21.14, B.1.177.637 Ct mean = 20.63,
338 p-value < 0.01 for both comparisons by unpaired Wilcoxon test, Figure 3c). This data suggests
339 that, unlike the results of the *in vitro* studies, B.1.177.637 replicates as efficiently as other 20E
340 genotypes *in vivo*, although mutations outside of the S protein could contribute to this result.

341 **Amino acid changes D1163Y and G1167V do not alter S protein stability**


342 As increased S protein stability could impact transmissibility by maintaining virion infectivity
343 during the intra-host transmission period, we assessed the temperature sensitivity of the

344 different S variants. For this, we subjected VSV particles pseudotyped with different S genotypes
345 to a range of temperatures for 15 minutes, after which we evaluated the surviving fraction.
346 Overall, no major differences in the degree to which the different S proteins lost infectivity upon
347 heat exposure were observed, with all S proteins showing a 50% reduction in infectivity at a
348 similar temperature range (39.8-42.2°C; p-value > 0.05 for all except Wuhan S genotype (D614)
349 versus 20E S genotype (A222V and D614G), where p-value = 0.01; Figure 3d). Hence, the D1163Y
350 and G1167V mutations do not seem to have a major impact in the thermal stability of the S
351 protein.

352 **Spike D1163Y and G1167V modestly reduce sensitivity to neutralization by existing antibody**
353 **immunity**

354 Positions 1163 and 1167 of the S protein have been reported to occur in both T and B cell SARS-
355 CoV-2 epitopes⁵²⁻⁵⁴. Moreover, numerous studies have shown that mutations in the S protein
356 can affect antibody neutralization^{30,31}. We therefore examined if the presence of D1163Y and
357 G1167V alters the neutralization capacity of convalescent sera using VSV pseudotyped with
358 either the 20E or B.1.177.637 S genotypes. In order to capture the potential influence of
359 different infecting variants on antibody neutralization, we tested the sensitivity of these
360 pseudotyped viruses to neutralization by sera from early (April 2020; First wave in Spain) or later
361 (October 2020; Second wave in Spain) in the pandemic, when newer variants were dominant^{6,36}.
362 Overall, B.1.177.637 genotype conferred a modest but statistically significant reduction in
363 sensitivity to neutralization by six serum samples tested from the early stage of the pandemic,
364 as measured by the titers required to inhibit viral entry by 80% (ID₈₀; mean = 6.75, range: 1.30-
365 17.68; p-value = 0.008 by paired t-test; Figure 4a). A statistically significant but smaller effect
366 was observed when the titers required to inhibit viral entry by 50% were examined (ID₅₀; mean
367 = 2.27, range: 1.61-3.54; p-value < 0.001 by paired t-test; Supplementary Fig.6). In contrast, both
368 20E and B.1.177.637 were equally susceptible to sera from patients infected during the second

369 wave (ID_{80} ; mean = 1.03, range: 0.87-1.23; p-value = 0.83 by paired t-test; Figure 4b). These
370 results indicate that the D1163Y and G1167V mutations can provide some degree of escape from
371 pre-existing antibody-based immunity relative to the 20E S genotype depending on the genomic
372 background of the infecting genotype. As a modest reduction in titers was observed with sera
373 from early in the pandemic (Figure 4a), which is more closely related to the current S genotype
374 present in approved vaccines^{55,56}, we examined if B.1.177.637 S genotype resulted in reduced
375 neutralization by sera from donors vaccinated with the BNT162b2 vaccine. No significant
376 differences in susceptibility to antibody neutralization from vaccinated donors were observed
377 between the two genotypes, indicating that VOI1163.7 is unlikely to alter the efficacy of vaccines
378 based on the Wuhan S genotype (Figure 4c).



380 **Figure 5. Antibody neutralization of 20E and B.1.177.637 variants.** The reciprocal titer at which
381 infection with the 20E S genotype (A222V and D614G) or B.1.177.637 S genotype (20E plus
382 D1163Y and G1167V) is reduced by 80% (ID_{80}) by sera from individuals infected during the early
383 stage of the pandemic in (a) or during a later stage of the pandemic (b) or from donors
384 vaccinated with the BNT162b2 vaccine (c). The mean and standard error of three replicates is
385 plotted.

386 Discussion

387 SARS-CoV-2 success is linked to its ability to infect and be transmitted. Mutations that emerge
388 independently several times and increase in frequency are likely to confer enhanced viral
389 infectivity, transmission, or immune evasion. The identification of such mutants is of great
390 importance, as they can significantly impact public health. In this work, we have identified two
391 mutations in the S protein that are likely to be beneficial for the virus based on several lines of
392 evidence. First, these mutations are highly variable within SARS-CoV-2 but conserved across the
393 closely related coronaviruses. Second, the vast majority of sequences harbouring these
394 mutations appear in clusters (Figure 1a and 1b). Third, the largest cluster, and therefore the
395 most successful in terms of transmission, includes both mutations together (Figure 1a and 1b).
396 Additionally, both positions have been reported as positively selected multiple times throughout
397 the SARS-CoV-2 phylogeny indicating a fitness advantage⁵⁷. Although either mutation in
398 isolation could be advantageous, their co-occurrence in a large cluster that has been sustained
399 for more than six months across Europe is suggestive of increased fitness when both mutations
400 are present together.

401 Positions 1163 and 1167 are found in the HR2 domain of the S protein, adjacent to the
402 transmembrane domain. Examination of available structural data suggests that G1167V might
403 alter the flexibility of the S protein stalk by both restricting the conformational freedom normally
404 conferred by the glycine residue and by introducing a hydrophobic side chain that will favour

405 burial in the HR2 coiled-coil leucine zipper of the pre-fusion state (Figure 2). This extensive
406 flexibility of S prefusion stalk seems to be unique to the SARS-CoV-2 S protein and has not been
407 reported for other class I fusion proteins¹⁸. The stalk flexibility has been suggested to increase
408 avidity for the host receptors by allowing the engagement of multiple S proteins¹⁸. Therefore,
409 stalk stabilization is likely to result in a reduced ability of S to bind receptors in the target cell.
410 Indeed, we find the B.1.177.637 genotype to have reduced infectivity compared to the 20E
411 genotype in both Vero and A549-hACE2-TMPRSS2 cells (Figure 3a, b). In contrast, viral load in
412 individuals infected with different S genotypes indicated that 20E and B.1.177.637 reach similar
413 degrees of viral replication *in vivo* (Figure 3c). This apparent discrepancy in the effect of the two
414 mutations on infectivity may stem from the differences of SARS-CoV-2 infection *in vivo* and in
415 the *in vitro* assay. A recent publication has suggested that the tyrosine-protein kinase receptor
416 UFO (AXL) is an important mediator of SARS-CoV-2 entry and may be of higher relevance for
417 infection of the lung than ACE2⁵⁸. The effect of entry via AXL in the two cell lines used may be
418 overshadowed by high levels of ACE2 expression. Alternatively, additional factors could underlie
419 this difference, including the presence of additional mutations outside of the S protein or
420 differences of viral loads across sampling times *in vivo* during the infection.

421 Increased temperature stability can potentially confer a fitness advantage to the virus by
422 reducing losses to infectivity during environmental transition between hosts. Hence, we also
423 examined whether these mutations altered the temperature stability of the virions. Overall, no
424 major difference in stability was observed between VSV pseudoparticles bearing the D614,
425 D614G, 20E, or B.1.177.637 S protein genotypes (Figure 3d). Hence, changes in protein stability
426 are unlikely to underlie the increased transmission of these variants.

427 Finally, as the S protein is a major target of the immune response¹², immune evasion represents
428 one possible consequence of mutations in this protein. Both S positions 1163 and 1167 are
429 embedded in experimentally confirmed T cell and B cell epitopes. For T cell epitopes, a predicted

430 HLA-II epitopes including position 1163 and 1167 has been experimentally verified to bind to
431 HLA DRB1*01:01, the prototype molecule for the DR supertype (epitope identifier in Immune
432 Epitope Data Base: 9006⁵⁹). Additionally, D1163 is included in a SARS-CoV-2 T cell epitope
433 eliciting T-cell responses in convalescent COVID-19 cases⁶⁰ as well as in SARS-CoV-2-naïve
434 individuals⁵³, indicating cross-reactivity in epitopes involving these regions. B cell linear epitopes
435 that span D1163 and G1167 have also been reported⁵², with D1163 belonging to a dominant
436 linear B cell epitope recognized by more than 40% COVID-19 patients used in the assay⁵⁴. D1163
437 is fully solvent exposed in available structure^{18,45}, making its side-chain easily accessible to
438 antibodies, providing a potential mechanism for altering antibody binding. To directly examine
439 whether the mutated S positions 1163 and 1167 influence susceptibility to pre-existing humoral
440 immunity, we examined the neutralization capacity of convalescent sera against the 20E variant
441 or B.1.177.637. For this, we used sera from both the first (April 2020) and second (October 2020)
442 waves of the infection in Spain, because an almost complete replacement of SARS-CoV-2 S
443 variants occurred between these two times of the pandemic in Spain³⁶. When utilizing sera from
444 donors infected during the first wave of the pandemic in Spain, we found a modest but
445 statistically significant reduction in susceptibility to neutralization of the B.1.177.637 S genotype
446 compared to the 20E S genotype of approximately 6-fold (Figure 4a). However, no difference in
447 neutralization was observed between the two variants when sera from patients infected during
448 the second wave was used (Figure 4b), highlighting variant-specific differences in antibody
449 responses. Overall, the magnitude of the observed reduction in neutralization susceptibility to
450 sera from individuals infected during the first wave was much less pronounced than that
451 observed for other genotypes implicated in immune evasion³¹. Nevertheless, the degree of
452 reduced neutralization required to confer a biologically relevant fitness advantage *in vivo* has
453 not been established, and even relatively small reductions in susceptibility to antibody
454 neutralizations could potentially confer a significant advantage to replication. Indeed, this has
455 been suggested to be the case in an immunosuppressed individual treated with convalescent

456 serum, where mutations selected during the course of treatment conferred a similar reduction
457 to that observed in the current study⁶¹. Finally, no evidence was found for reduced neutralization
458 by sera from donors immunized with the BNT162b2 vaccine (Figure 4c), which is based on the
459 Wuhan S genotype, indicating antibody immunity elicited by Pfizer-BioNTech COVID-19 vaccine
460 (BNT162b2; February 2021) would not be affected by amino acid replacements in 1163 and 1167
461 sites in S protein.

462 Although further experiments are needed to decipher the mechanisms by which the two S
463 mutations identified could confer a selective advantage to the virus, the evidence presented
464 supports B.1.177.637 as a VOI (VOI1163.7.V1) according to recently published criteria⁴. First,
465 amino acid replacements in S protein: D1163Y and G1167V lead to changes associated with
466 suspected phenotypic change because of the rigidity it poses to the S protein. Second, the
467 genotype showed moderate but significantly lower antibody susceptibility compared to 20E S
468 genotype. And third, it has been identified to cause community transmission, appearing in
469 multiple COVID-19 cases, and detected in multiple countries. Additionally, a subgroup within
470 B.1.177.637 (denoted as VOI1163.7.V2) includes two additional mutations leading to amino acid
471 changes in S with established phenotypic impact on humoral immunity: E484K⁶² and 141-
472 144Del^{40,63}.

473 Whether VOI1163.7.V1 and VOI1163.7.V2 will continue to increase in frequency and accumulate
474 additional mutations that could improve its fitness and/or present challenges to vaccines or
475 diagnostics remains to be seen. However, their characterization as VOI would help to discover if
476 enough evidence holds to consider them VOC and therefore required monitoring.

477 **Methods**

478 **Whole-genome sequencing and genome assembly of SeqCOVID consortium sequences**

479 A total of 5,017 clinical samples were received, sequenced, and analysed by the SeqCOVID
480 consortium from all autonomous communities of Spain. These samples were confirmed as SARS-
481 CoV-2 positive by RT-PCR carried out by Clinical Microbiology Services from each hospital.
482 Sequencing of the samples has been approved by the ethics committee: Comité Ético de
483 Investigación de Salud Pública y Centro Superior de Investigación en Salud Pública (CEI DGSP-
484 CSISP) Nº 20200414/05. All sequences are available at GISAID under the accession numbers
485 detailed in Supplementary table 4.

486 For sequencing, RNA samples were retro-transcribed into cDNA. SARS-CoV-2 complete genome
487 amplification was performed in two multiplex PCR, according to the protocol developed by the
488 ARTIC network⁶⁴, using the V3 multiplex primers scheme⁶⁵. From this step, two amplicon pools
489 were prepared, combined, and used for library preparation. The genomic libraries were
490 constructed with the Nextera DNA Flex Sample Preparation kit (Illumina Inc., San Diego, CA)
491 according to the manufacturer's protocol, with 5 cycles for indexing PCR. Whole-genome
492 sequencing was performed in the MiSeq platform (2×200 cycles paired-end run; Illumina).

493 Reads obtained were processed through a bioinformatic pipeline based on iVar⁶⁶, available at
494 <https://gitlab.com/fisabio-ngs/sars-cov2-mapping>. The first step in the pipeline removed human
495 reads with Kraken⁶⁷; then fastq files were filtered using fastp⁶⁸ v 0.20.1 (arguments employed:
496 --cut tail, --cut-window-size, --cut-mean-quality, -max_len1, -max_len2). Finally, mapping and
497 variant calling were performed with iVar v 1.2, and quality control assessment was carried out
498 with MultiQC⁶⁹.

499 **Analysis of the *spike* gene of sarbecoviruses related to SARS-CoV-2**

500 14 sequences including SARS-COV-2 belonging to sarbecoviruses, sequences were annotated
501 with annotation files available at NCBI database in order to locate the *spike* gene coordinates
502 (accession numbers are available at supplemental table 1). For each sequence, nucleotide
503 coordinates belonging to this gene were extracted with EMBOSS⁷⁰. The 14 sequences harbouring
504 the *spike* gene were concatenated and aligned with MEGA-X⁷¹ using amino acids with ClustalW
505 algorithm with default options (alignment is available at
506 https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2)

507 **Sampling SARS-CoV-2 from non-Spanish consortium sequences**

508 To build the global alignment, sequences were downloaded from GISAID¹ including all the
509 pandemic periods since the first known case sequenced (from 24 December 2019) until the last
510 sample on 22 December 2020. We used two filters to select the dataset: sequences with more
511 than 29,000 bp, and sequences with known dates of sampling. Sequences downloaded from
512 GISAID were aligned against the SARS-CoV-2 reference genome⁷² using MAFFT⁷³, omitting all
513 insertions and getting an alignment length of 29,903 bp. The final alignment constructed
514 included 270,869 sequences, all sequences with GISAID ID used for this study are available in
515 Supplementary Table 5.

516 **Frequency and detection of mutated positions**

517 Single nucleotide variants were detected using the global dataset alignment, generating a VCF
518 file with SNP-sites⁷⁴ v 2.5.1 (argument employed: -v), using the reference genome as the
519 reference bases for detecting mutations. This VCF file was processed with a Python script
520 (available at https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2) to assess all
521 mutated samples by position, calculating the frequencies of the global dataset and annotating
522 sequences with the detected mutations. After that, the mutated positions were annotated with

523 snpEff⁷⁵ v 5.0 using SARS-CoV-2 reference (Wuhan first sequenced) database annotation
524 (arguments employed: -c, -noStats, -no-downstream, -no-upstream, NC_045512.2).

525 Genotypes detected that involved mutations in 1163 and 1167 such as B.1.177.637 and cluster
526 163.654 were represented in a circos plot with the R package circlize⁷⁶ v 0.4.12.1004. Nucleotide
527 coordinates of SARS-CoV-2 are plotted in a non-closed circle, circle is annotated and coloured
528 with genes of the virus, and mutated nucleotide positions of each genotype are connected
529 between them through lines.

530 **Alignments**

531 For the phylogenetic analysis, a reduced dataset was selected from the 270,869 sequences.
532 Duplicated sequences were removed with seqkit v 0.13.2 (arguments employed: rmdup -s).
533 8,397 sequences were selected at random with the same temporal distribution by month as the
534 initial dataset by Python scripting (available at [https://github.com/PathoGenOmics/
535 B.1.177.637_SARS-CoV-2](https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2)). The 8,397 sequences were concatenated with 2,053 sequences
536 selected as indicate above because harboured amino acid replacements in D1163 and G1167 of
537 the S protein and resulted in an alignment of 10,450 sequences (Supplementary Table 6).

538 The dataset to represent 20I/501Y.V1 phylogenetic relationships include 3,067 randomly
539 selected samples identified by Pangolin typing system ([https://github.com/cov-
540 lineages/pangolin](https://github.com/cov-lineages/pangolin)) as lineage B.1.1.7 plus the 33 sequences with amino acid replacements in
541 D1163 and/or G1167 (Supplementary Table 7).

542 For all the alignments, problematic positions reported by Lanfear, R.⁷⁷ were masked for the
543 phylogenetic reconstruction using masked_alignment.sh script.

544 **Phylogenetic analysis**

545 Maximum-likelihood phylogenies in Figure 1 and supplementary Supplementary Fig.2, S4 and S5
546 were reconstructed from the masked alignment using IQ-TREE⁷⁸ v 1.6.12 with GTR model and
547 collapsing near-zero branches (arguments employed: -czb, -m GTR). The phylogenies were
548 rooted in the reference sequence from Wuhan⁷² on 2019-12-24. The phylogenies were
549 annotated and visualized with iTOL⁷⁹ v 4.

550 The phylogeny in Supplementary Video S1, composed by 10,450 sequences, was build up with
551 Nextstrain pipeline (available at <https://github.com/nextstrain/augur>) in order to monitor and
552 visualize temporal and geographical transmission of B.1.177.637. This dataset file is available at
553 https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2.

554 **Clusters of transmission involving 1163 and 1167 S amino acid replacements.**

555 We used the phylogeny of 10,450 sequences enriched with all sequences mutated in 1163 and
556 1167 to quantify the minimum number of mutational events involving positions 1163 and 1167
557 in S protein. We first defined which mutations characterize internal nodes using R packages:
558 tidytree v 0.3.3 and treeio v 1.14.3⁸⁰. We then depicted monophyletic clusters sharing at least
559 one of the two mutations. Transmission clusters were defined as all sequences that: i) are
560 derived from an internal node characterized by the same nucleotide mutation involving 1163 or
561 1167 amino acid replacements, ii) include more than one sequence, and iii) at least 95% of
562 sequences share the nucleotide mutation. Additionally, redundant nodes were eliminated,
563 keeping the ancestral node of the cluster (harbouring the largest number of leaves). Sequences
564 with at least one mutation but not in clusters were counted as single events of mutation in the
565 phylogeny.

566 **Structural analysis of 1163 and 1167 S amino acid replacements.**

567 The atomic coordinates for S protein in pre-fusion state was retrieved from the CHARMM-GUI
568 COVID-19 Archive (<http://www.charmm-gui.org/docs/archive/covid19>). The atomic coordinates
569 for S protein in post-fusion state were retrieved from Protein Data Bank (PDB: 6XRA¹⁸ and PDB:
570 6LXT⁸¹). Mutations were introduced using single mutation tool embedded in COOT⁸² and figures
571 were generated with PyMOL (www.pymol.org).

572 **SARS-CoV-2 pseudotyped vesicular stomatitis virus production, titration, and thermal stability** 573 **evaluation**

574 Mutations were introduced into a plasmid encoding a codon-optimized S protein¹⁶ by site
575 directed mutagenesis (see Supplementary table 8 for primers). All mutations were verified by
576 Sanger sequencing (see Supplementary table 9 for primers). To evaluate the efficiency of virus
577 production, three transfections in HEK293 cells (CRL-1573 from ATCC) were performed for each
578 plasmid to generate pseudotyped VSV harbouring the indicated S protein⁸³. The titers of the
579 virus produced were then assayed by serial dilution, followed by infection of either Vero cells
580 (CCL-81 from ATCC) or A549 cells expressing ACE2 and TMPRSS2 (InvivoGen catalog code a549-
581 hacc2tpsa), and counting of GFP positive cells (focus forming units; FFU) at 16 hours post
582 infection. Statistical comparisons were performed by unpaired t-test (R package: stats v 3.6.1)
583 with normalized logarithmic data. For assessing thermal stability, 1000 FFU (as measured on
584 Vero cells) were incubated for 15 minutes at 30.4, 31.4, 33, 35.2, 38.2, 44.8, 47, 48.6 or 49.6°C
585 before addition to Vero cells previously seeded in a 96 well plate (10,000 cells/well). GFP signal
586 in each well was determined 16 hours post-infection using an Incucyte S3 (Essen Biosciences).
587 The mean GFP signal observed in several mock-infected wells was subtracted from all infected
588 wells, followed by standardization of the GFP signal to the mean GFP signal from wells incubated
589 at 30.4°C. Finally, a three parameter log-logistic function was fitted to the data using the drc
590 package v 3.0-1 in R (LL.3 function) and the temperature resulting in 50% inhibition calculated
591 using the drc ED function. Statistical differences in the temperature resulting in 50% reduction

592 of infection was evaluated using the drc EDcomp function. The data and scripts for analysing the
593 temperature resistance of the different mutants is available at
594 https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2.

595 **Evaluation of neutralization by convalescent sera and efficacy of virus particle production.**

596 Pseudotyped VSV bearing 20E or B.1.177.637 S variants were evaluated for sensitivity to
597 neutralization by convalescent sera as previously described⁸³ with slight modifications. Briefly,
598 16-hours post-infection, GFP signal in each well was determined using an Incucyte S3 (Essen
599 Biosciences). The mean GFP signal observed in several mock-infected wells was subtracted from
600 all infected wells, followed by standardization of the GFP signal in each well infected with
601 antibody-treated virus to that of the mean GFP signal from wells infected with mock-treated
602 virus. Any negative values resulting from background subtraction were arbitrarily assigned a low,
603 non-zero value (10^{-5}). The serum dilutions were then converted to their reciprocal, their
604 logarithm (Log_{10}) was taken, and the dose resulting in 50% (ID50) or 80% (ID80) reduction in GFP
605 signal was calculated in R using the drc package v 3.0-1. A two-parameter log-logistic regression
606 (LL2 function) was used for all samples except when a three-parameter logistic regression
607 provided a significant improvement to fit, as judged by the ANOVA function in the drc package
608 (e.g. $p < 0.05$ following multiple testing correction using the Bonferroni method). The script for
609 calculating the ID50 and ID80 as well as the standardized GFP signal for each condition is
610 available at https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2. For the first wave,
611 serum samples and data from patients included in this study were provided by the Consorcio
612 Hospital General de Valencia Biobank, integrated in the Valencian Biobanking Network, and they
613 were processed following standard operating procedures with the appropriate approval of the
614 Ethics and Scientific Committees. All first wave samples were obtained from donors that were
615 admitted to the intensive care unit and were collected during April 2020. For the second wave
616 donors, sera were obtained (October 2020) from severe COVID-19 patients requiring inpatient

617 treatment at Hospital Universitario y Politécnico La Fe de Valencia. Similarly, samples from
618 immunized donors were collected at Hospital Universitario y Politécnico La Fe de Valencia from
619 hospital health-workers, with no previous history of SARS-COV-2 infection, and after receiving a
620 second dose of Pfizer-BioNTech COVID-19 vaccine (BNT162b2; February 2021). All samples from
621 Hospital Universitario y Politécnico La Fe de Valencia were collected after informed written
622 consent and the project has been approved by the ethical committee and institutional review
623 board (registration number 2020-123-1).

624 **Acknowledgments**

625 We want to particularly acknowledge the patients and the Consorcio Hospital General de
626 Valencia Biobank integrated in the Valencian Biobanking Network for their collaboration, as well
627 as the patients and hospital staff at Hospital Universitario y Politécnico La Fe de Valencia. In
628 addition, the authors would like to thank Gert Zimmer (Institute of Virology and Immunology,
629 Mittelhäusern/Switzerland), Stefan Pohlmann, and Markus Hoffmann (German Primate Center,
630 Infection Biology Unit, Goettingen/Germany) for providing the reagents required for the
631 generation of VSV pseudotyped viruses and the codon-optimized S plasmid.

632 Also, we want to acknowledge all the efforts from different laboratories and authorities
633 submitting all possible sequences of SARS-CoV-2 worldwide and making them available on the
634 GISAID platform.

635 **Funding**

636 M.C. and R.G. are supported by Ramón y Cajal program from Ministerio de Ciencia. This work
637 was funded by the Instituto de Salud Carlos III project COV20/00140 and COV20/00437, Spanish
638 National Research Council project CSIC-COV19-021 and CSIC-COVID19-082, and the Generalitat
639 Valenciana (SEJI/2019/011 and Covid_19-SCI).

640 Action co-financed by the European Union through the Operational Program of the European
641 Regional Development Fund (ERDF) of the Valencian Community 2014-2020.

642 **References**

- 643 1. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
644 contribution to global health. *Glob Chall* **1**, 33-46 (2017).
- 645 2. Hadfield, J. *et al.* Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*
646 **34**, 4121-4123 (2018).
- 647 3. Luring, A.S. & Hodcroft, E.B. Genetic Variants of SARS-CoV-2-What Do They Mean?
648 *Jama* **325**, 529-531 (2021).
- 649 4. WHO. COVID-19 Weekly Epidemiological Update 2021-02-25 .
650 ([https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210225-weekly-epi-update-voc-special-edition.pdf)
651 [reports/20210225-weekly-epi-update-voc-special-edition.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210225-weekly-epi-update-voc-special-edition.pdf), 2021).
- 652 5. Volz, E. *et al.* Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on
653 Transmissibility and Pathogenicity. *Cell* **184**, 64-75.e11 (2020).
- 654 6. Hodcroft, E.B. *et al.* Emergence and spread of a SARS-CoV-2 variant through Europe in
655 the summer of 2020. *medRxiv*, 2020.10.25.20219063. Preprint at
656 <https://www.medrxiv.org/content/10.1101/2020.10.25.20219063v2> (2020).
- 657 7. Oude Munnink, B.B. *et al.* Transmission of SARS-CoV-2 on mink farms between humans
658 and mink and back to humans. *Science* **371**, 172 (2021).
- 659 8. Richard, D., Owen, C.J., van Dorp, L. & Balloux, F. No detectable signal for ongoing
660 genetic recombination in SARS-CoV-2. *bioRxiv*, 2020.12.15.422866. Preprint at
661 <https://www.biorxiv.org/content/10.1101/2020.12.15.422866v1> (2020).
- 662 9. Welkers, M.R.A., Han, A.X., Reusken, C. & Eggink, D. Possible host-adaptation of SARS-
663 CoV-2 due to improved ACE2 receptor binding in mink. *Virus Evol* **7**, veaa094 (2021).

- 664 10. Young, B.E. *et al.* Effects of a major deletion in the SARS-CoV-2 genome on the severity
665 of infection and the inflammatory response: an observational cohort study. *Lancet*
666 **396**, 603-611 (2020).
- 667 11. Chand, M. *et al.* Investigation of novel SARS-COV-2 variant Variant of Concern
668 202012/01. (Public Health England,
669 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf)
670 [ment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf), 2020).
- 671 12. Walls, A.C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
672 Glycoprotein. *Cell* **181**, 281-292.e6 (2020).
- 673 13. Salvatori, G. *et al.* SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for
674 vaccines. *Journal of Translational Medicine* **18**, 222 (2020).
- 675 14. Turoňová, B. *et al.* In situ structural analysis of SARS-CoV-2 spike reveals flexibility
676 mediated by three hinges. *Science* **370**, 203 (2020).
- 677 15. Hoffmann, M., Kleine-Weber, H. & Pöhlmann, S. A Multibasic Cleavage Site in the Spike
678 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**, 779-
679 784.e5 (2020).
- 680 16. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
681 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- 682 17. Kielian, M. Mechanisms of Virus Membrane Fusion Proteins. *Annu Rev Virol* **1**, 171-89
683 (2014).
- 684 18. Cai, Y. *et al.* Distinct conformational states of SARS-CoV-2 spike protein. *Science* **369**,
685 1586 (2020).
- 686 19. Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
687 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827.e19 (2020).
- 688 20. Hou, Y.J. *et al.* SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
689 transmission in vivo. *Science* **370**, 1464-1468 (2020).

- 690 21. Plante, J.A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* (2020).
- 691 22. Zhou, B. *et al.* SARS-CoV-2 spike D614G change enhances replication and transmission.
692 *Nature* (2021).
- 693 23. Daniloski, Z. *et al.* The Spike D614G mutation increases SARS-CoV-2 infection of
694 multiple human cell types. *Elife* **10**(2021).
- 695 24. Larsen, H.D. *et al.* Preliminary report of an outbreak of SARS-CoV-2 in mink and mink
696 farmers associated with community spread, Denmark, June to November 2020. *Euro*
697 *Surveill* **26**(2021).
- 698 25. Rodrigues, J. *et al.* Insights on cross-species transmission of SARS-CoV-2 from
699 structural modeling. *PLoS Comput Biol* **16**, e1008449 (2020).
- 700 26. Hodcroft, E.B. CoVariants: SARS-CoV-2 Mutations and Variants of Interest.
701 (<https://covariants.org/variants/>, 2021).
- 702 27. Leung, K., Shum, M.H., Leung, G.M., Lam, T.T. & Wu, J.T. Early transmissibility
703 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom,
704 October to November 2020. *Euro Surveill* **26**(2021).
- 705 28. Galloway, S. *et al.* Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States,
706 December 29, 2020–January 12, 2021. *MMWR. Morbidity and Mortality Weekly Report*
707 **70**(2021).
- 708 29. Davies, N.G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7
709 in England. *Science*, eabg3055 (2021).
- 710 30. Wang, Z. *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating
711 variants. *Nature* (2021).
- 712 31. Wibmer, C.K. *et al.* SARS-CoV-2 501Y.V2 escapes neutralization by South African
713 COVID-19 donor plasma. *bioRxiv*, 2021.01.18.427166. Preprint at
714 <https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2> (2021).

- 715 32. Muik, A. *et al.* Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2
716 vaccine-elicited human sera. *bioRxiv*, 2021.01.18.426984. Preprint at
717 <https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1> (2021).
- 718 33. Madhi, S.A. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19
719 vaccine against the B.1.351 variant in South Africa. *medRxiv*, 2021.02.10.21251247.
720 Preprint at <https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1>
721 (2021).
- 722 34. Washington, N.L. *et al.* Genomic epidemiology identifies emergence and rapid
723 transmission of SARS-CoV-2 B.1.1.7 in the United States. *medRxiv*,
724 2021.02.06.21251159. Preprint at
725 <https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1> (2021).
- 726 35. Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory
727 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in
728 South Africa. *medRxiv*, 2020.12.21.20248640. Preprint at
729 <https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1> (2020).
- 730 36. López, M.G. *et al.* The first wave of the Spanish COVID-19 epidemic was associated
731 with early introductions and fast spread of a dominating genetic variant. *medRxiv*,
732 2020.12.21.20248328. Preprint at
733 <https://www.medrxiv.org/content/10.1101/2020.12.21.20248328v1> (2020) (2020).
- 734 37. Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
735 genomic epidemiology. *Nature Microbiology* **5**, 1403-1407 (2020).
- 736 38. Nelson, G. *et al.* Molecular dynamic simulation reveals E484K mutation enhances spike
737 RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations
738 (501Y.V2 variant) induces conformational change greater than N501Y mutant alone,
739 potentially resulting in an escape mutant. *bioRxiv*, 2021.01.13.426558. Preprint at
740 <https://www.biorxiv.org/content/10.1101/2021.01.13.426558v1> (2021).

- 741 39. Liu, Z. *et al.* Landscape analysis of escape variants identifies SARS-CoV-2 spike
742 mutations that attenuate monoclonal and serum antibody neutralization. *bioRxiv*,
743 2020.11.06.372037. Preprint at
744 <https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2> (2021).
- 745 40. McCallum, M. *et al.* N-terminal domain antigenic mapping reveals a site of
746 vulnerability for SARS-CoV-2. *bioRxiv*, 2021.01.14.426475. Preprint at
747 <https://www.biorxiv.org/content/10.1101/2021.01.14.426475v1> (2021).
- 748 41. Huang, Y., Yang, C., Xu, X.-f., Xu, W. & Liu, S.-w. Structural and functional properties of
749 SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta*
750 *Pharmacologica Sinica* **41**, 1141-1149 (2020).
- 751 42. Xia, S. *et al.* Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1
752 domain in spike protein. *Cellular & Molecular Immunology* **17**, 765-767 (2020).
- 753 43. Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus:
754 implications for virus origins and receptor binding. *The Lancet* **395**, 565-574 (2020).
- 755 44. Xia, S. *et al.* Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike
756 Protein HR1 and HR2 Domains. *Int J Mol Sci* **19**(2018).
- 757 45. Fan, X., Cao, D., Kong, L. & Zhang, X. Cryo-EM analysis of the post-fusion structure of
758 the SARS-CoV spike glycoprotein. *Nature Communications* **11**, 3618 (2020).
- 759 46. Woo, H. *et al.* Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein
760 Model in a Viral Membrane. *The Journal of Physical Chemistry B* **124**, 7128-7137
761 (2020).
- 762 47. Zhang, L. *et al.* SARS-CoV-2 spike-protein D614G mutation increases virion spike
763 density and infectivity. *Nature Communications* **11**, 6013 (2020).
- 764 48. Yurkovetskiy, L. *et al.* Structural and Functional Analysis of the D614G SARS-CoV-2
765 Spike Protein Variant. *Cell* **183**, 739-751.e8 (2020).

- 766 49. Wang, Y. *et al.* The Infectivity and Antigenicity of Epidemic SARS-CoV-2 Variants in the
767 United Kingdom. *Research Square* (2021).
- 768 50. Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay
769 for the rapid and sensitive determination of multi-species type I interferon. *PLoS One*
770 **6**, e25858 (2011).
- 771 51. Weissman, D. *et al.* D614G Spike Mutation Increases SARS CoV-2 Susceptibility to
772 Neutralization. *Cell Host & Microbe* **29**, 23-31.e4 (2021).
- 773 52. Li, Y. *et al.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in
774 COVID-19 patients. *Cellular & Molecular Immunology* **17**, 1095-1097 (2020).
- 775 53. Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
776 humans. *Science* **370**, 89-94 (2020).
- 777 54. Yi, Z. *et al.* Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19
778 convalescent population. *Emerg Microbes Infect* **9**, 1988-1996 (2020).
- 779 55. Zhao, J. *et al.* COVID-19: Coronavirus Vaccine Development Updates. *Frontiers in*
780 *Immunology* **11**, 3435 (2020).
- 781 56. Izda, V., Jeffries, M.A. & Sawalha, A.H. COVID-19: A review of therapeutic strategies
782 and vaccine candidates. *Clinical Immunology* **222**, 108634 (2021).
- 783 57. Pond, S. Natural selection analysis of global SARS-CoV-2/COVID-19 enabled by data
784 from GISAID. ([https://observablehq.com/@spond/revised-sars-cov-2-analytics-](https://observablehq.com/@spond/revised-sars-cov-2-analytics-page?collection=@spond/sars-cov-2)
785 [page?collection=@spond/sars-cov-2](https://observablehq.com/@spond/sars-cov-2)).
- 786 58. Wang, S. *et al.* AXL is a candidate receptor for SARS-CoV-2 that promotes infection of
787 pulmonary and bronchial epithelial cells. *Cell Research* **31**, 126-140 (2021).
- 788 59. Vita, R. *et al.* The immune epitope database (IEDB) 3.0. *Nucleic Acids Research* **43**,
789 D405-D412 (2015).

- 790 60. Tarke, A. *et al.* Comprehensive analysis of T cell immunodominance and
791 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Reports Medicine*
792 **2**, 100204 (2021).
- 793 61. Kemp, S.A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature*
794 (2021).
- 795 62. Collier, D.A. *et al.* SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited,
796 convalescent and monoclonal antibodies. *medRxiv*, 2021.01.19.21249840. Preprint at
797 <https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v4> (2021).
- 798 63. Wang, P. *et al.* Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
799 *bioRxiv*, 2021.01.25.428137. Preprint at
800 <https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2> (2021).
- 801 64. Quick, J. nCoV-2019 sequencing protocol. ([https://www.protocols.io/view/ncov-2019-](https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w.pdf)
802 [sequencing-protocol-bbmuik6w.pdf](https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w.pdf), 2020).
- 803 65. Artic-network/artic-ncov2019. (Artic-network, [https://github.com/artic-network/artic-](https://github.com/artic-network/artic-ncov2019)
804 [ncov2019](https://github.com/artic-network/artic-ncov2019), 2020).
- 805 66. Grubaugh, N.D. *et al.* An amplicon-based sequencing framework for accurately
806 measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol* **20**, 8 (2019).
- 807 67. Wood, D.E. & Salzberg, S.L. Kraken: ultrafast metagenomic sequence classification
808 using exact alignments. *Genome Biol* **15**, R46 (2014).
- 809 68. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
810 *Bioinformatics* **34**, i884-i890 (2018).
- 811 69. Ewels, P., Magnusson, M., Lundin, S. & Källér, M. MultiQC: summarize analysis results
812 for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047-8 (2016).
- 813 70. Rice, P., Longden, I. & Bleasby, A. EMBOSS: The European molecular biology open
814 software suite. *Trends in Genetics* **16**, 276-277 (2000).

- 815 71. Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary
816 Genetics Analysis across Computing Platforms. *Mol Biol Evol* **35**, 1547-1549 (2018).
- 817 72. Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China.
818 *Nature* **579**, 265-269 (2020).
- 819 73. Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple
820 sequence alignment based on fast Fourier transform. *Nucleic Acids Res* **30**, 3059-66
821 (2002).
- 822 74. Page, A.J. *et al.* SNP-sites: rapid efficient extraction of SNPs from multi-FASTA
823 alignments. *Microb Genom* **2**, e000056 (2016).
- 824 75. Cingolani, P. *et al.* A program for annotating and predicting the effects of single
825 nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster*
826 strain w11118; iso-2; iso-3. *Fly* **6**, 80-92 (2012).
- 827 76. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances
828 circular visualization in R. *Bioinformatics* **30**, 2811-2812 (2014).
- 829 77. Lanfear, R. A global phylogeny of SARS-CoV-2 sequences from GISAID. (Zenodo, 2020).
- 830 78. Nguyen, L.T., Schmidt, H.A., von Haeseler, A. & Minh, B.Q. IQ-TREE: a fast and effective
831 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* **32**,
832 268-74 (2015).
- 833 79. Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new
834 developments. *Nucleic Acids Research* **47**, W256-W259 (2019).
- 835 80. Wang, L.G. *et al.* Treeio: An R Package for Phylogenetic Tree Input and Output with
836 Richly Annotated and Associated Data. *Mol Biol Evol* **37**, 599-603 (2020).
- 837 81. Xia, S. *et al.* Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly
838 potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high
839 capacity to mediate membrane fusion. *Cell Research* **30**, 343-355 (2020).

- 840 82. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot.
841 *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).
842 83. Gozalbo-Rovira, R. *et al.* SARS-CoV-2 antibodies, serum inflammatory biomarkers and
843 clinical severity of hospitalized COVID-19 patients. *J Clin Virol* **131**, 104611 (2020).

844 **Author contributions**

845 PRR: Conceptualization, Methodology, Formal Analysis, Investigation, Visualization, Writing
846 Original Draft.

847 CFG: Conceptualization, Methodology, Formal Analysis, Writing Original Draft.

848 ACO: Formal Analysis, Review and edit draft.

849 MGL: Formal Analysis, Review and edit draft.

850 SJS: Software, Validation, Review and edit draft.

851 ICM: Methodology, Resources, Review and edit draft.

852 PRH: Investigation, Review and edit draft.

853 MTP: Methodology, Resources, Review and edit draft.

854 MAB: Investigation, Methodology, Review and edit draft.

855 GD: Methodology, Software, Data Curation, Review and edit draft.

856 LLM: Methodology, Project Administration, Review and edit draft.

857 MG: Resources, Review and edit draft.

858 MMA: Resources, Review and edit draft.

859 MDG: Resources, Review and edit draft.

860 JLP: Resources, Review and edit draft.

861 FG: Funding, Project Administration, Supervision, Review and edit draft.
862 IC: Funding, Project Administration, Supervision, Review and edit draft.
863 AM: Formal analysis, Writing Original Draft.
864 RG: Conceptualization, Methodology, Formal Analysis, Writing Original Draft, Supervision,
865 Funding.
866 MC: Conceptualization, Methodology, Investigation, Formal Analysis, Writing Original Draft,
867 Supervision, Funding.

868 **List of SeqCOVID consortium members**

869 Iñaki Comas (icomas@ibv.csic.es), Fernando González-Candelas (fernando.gonzalez@uv.es),
870 Galo A. Goig-Serrano (ggoig@ibv.csic.es), Álvaro Chiner-Oms (achiner@ibv.csic.es), Irving
871 Cancino-Muñoz (icancino@ibv.csic.es), Mariana Gabriela López (mglopez@ibv.csic.es), Manoli
872 Torres-Puente (mtorres@ibv.csic.es), Inmaculada Gómez (igomez@ibv.csic.es), Santiago
873 Jiménez-Serrano (sjimenez@ibv.csic.es), Lidia Ruiz-Roldán (lidiaroldan@gmail.com), María
874 Alma Bracho (bracho_alm@gva.es), Neris García-González (neris@uv.es), Llúcia Martínez Priego
875 (martinez_lucpri@gva.es), Inmaculada Galán-Vendrell (galan_inm@gva.es), Paula Ruiz-Hueso
876 (ruiz_pau@gva.es), Griselda De Marco (demarco_gri@gva.es), M^a Loreto Ferrús Abad
877 (ferrus_mlo@gva.es), Sandra Carbó-Ramírez (carbo_sanram@gva.es), Mireia Coscollá
878 (mireia.coscolla@uv.es), Paula Ruiz Rodríguez (ruizro5@alumni.uv.es), Giuseppe D'Auria
879 (dauria_giu@gva.es), Francisco Javier Roig Sena (roig_fco@gva.es), Hermelinda Vanaclocha
880 Luna (vanaclocha_her@gva.es), Isabel San Martín Bastida (isanmartin@rjb.csic.es), Daniel
881 García Souto (danielgarciasouto@gmail.com), Ana Pequeño Valtierra (ana.pequeno@usc.es),
882 Jose M. C. Tubio (jmctubio@gmail.com), Fco. Javier Temes Rodríguez (fjtemes@gmail.com),
883 Jorge Rodríguez-Castro (jorge.rodriguez@usc.es), Martín Santamarina García
884 (martin.santamarina.garcia@usc.es), Nuria Rabella Garcia (nrabella@sanpau.cat), Ferrán

885 Navarro Risueño (fnavarror@santpau.cat), Elisenda Miró Cardona (emiro@santpau.cat),
886 Manuel Rodríguez-Iglesias (manuel.rodriguez Iglesias@uca.es), Fátima Galán-Sánchez
887 (fatima.galan@uca.es), Salud Rodríguez-Pallares (salud361@gmail.com), María de Toro
888 (mthernando@riojasalud.es), María Pilar Bea-Escudero (mpbea@riojasalud.es), José Manuel
889 Azcona-Gutiérrez (jmazcona@riojasalud.es), Miriam Blasco-Alberdi (mblasco@riojasalud.es),
890 Alfredo Mayor (alfredo.mayor@isglobal.org), Alberto L. García-Basteiro (alberto.garcia-
891 basteiro@isglobal.org), Gemma Moncunill (gemma.moncunill@isglobal.org), Carlota Dobaño
892 (carlota.dobano@isglobal.org), Pau Cisteró (pau.cistero@isglobal.org), Oriol Mitjà
893 (omitja@flsida.org), Camila González-Beiras (cgonzalez@flsida.org), Martí Vall-Mayans
894 (mvall@flsida.org), Marc Corbacho-Monné (mcorbacho@flsida.org), Andrea Alemany
895 (ealemany@gmail.com), Darío García de Viedma (dgviedma2@gmail.com), Laura Pérez-Lago
896 (lperezg00@gmail.com), Marta Herranz (m_herranz01@hotmail.com), Jon Sicilia
897 (jsiciliamambrilla@gmail.com), Pilar Catalán (pcatalan.hgugm@salud.madrid.org), Julia Suárez
898 (julia.suarez@iisgm.com), Patricia Muñoz (pmunoz@hggm.es), Cristina Muñoz-Cuevas
899 (cristina.munozc@salud-juntaex.es), Guadalupe Rodríguez Rodríguez
900 (guadalupe.rodriguez@salud-juntaex.es), Juan Alberola Enguñados (juan.alberola@uv.es), Jose
901 Miguel Nogueira Coito (Jose.M.Nogueira@uv.es), Juan José Camarena Miñana
902 (juan.camarena@uv.es), Antonio Rezusta López (arezusta@unizar.es), Alexander Tristancho
903 Baró (aitristancho@salud.aragon.es), Ana Milagro Beamonte (amilagro@salud.aragon.es),
904 Nieves Martínez Cameo (nmcameo@gmail.com), Yolanda Gracia Grataloup
905 (ygrataloup@yahoo.es), Elisa Martró (emartro@igtp.cat), Antoni E. Bordoy (aescalas@igtp.cat),
906 Anna Not (anot@igtp.cat), Adrián Antuori (adrian.antuori@gmail.com), Anabel Fernández
907 (afernandezn.ics@gencat.cat), Nona Romaní (nonaromani@gmail.com), Rafael Benito Ruesca
908 (rbenito@unizar.es), Sonia Algarate Cajo (sonialgarate@gmail.com), Jessica Bueno Sancho
909 (jbuenosan@salud.aragon.es), Jose Luis del Pozo (jdelpozo@unav.es), Jose Antonio Boga Riveiro
910 (joseantonio.boga@sespa.es), Cristián Castelló Abietar (crcaab@hotmail.com), Susana Rojo

911 Alba (ssnrj4@gmail.com), Marta Elena Álvarez Argüelles (martaealvarez@gmail.com), Santiago
912 Melón García (santiago.melon@sespa.es), Maitane Aranzamendi Zaldumbide
913 (maitane.aranzamendizaldumbide@osakidetza.eus), Óscar Martínez Expósito
914 ("OSCAR.MARTINEZEXPOSITO@osakidetza.eus"), Mikel Gallego Rodrigo
915 ("MIKEL.GALLEGORODRIGO@osakidetza.eus"), Maialen Larrea Ayo
916 ("MAIALEN.LARREAYO@osakidetza.eus"), Nerea Antona Urieta
917 ("NEREA.ANTONAURIETA@osakidetza.eus"), Andrea Vergara Gómez (vergara@clinic.cat),
918 Miguel J Martínez Yoldi (myoldi@clinic.cat), Jordi Vila Estapé (jvila@clinic.cat), Elisa Rubio García
919 (elrubio@clinic.cat), Aida Peiró-Mestres (aida.peiro@isglobal.org), Jessica Navero-Castillejos
920 (jessica.navero@isglobal.org), David Posada (dposada@uvigo.es), Diana Valverde
921 (dianaval@uvigo.es), Nuria Estévez (nuestevez@uvigo.es), Iria Fernández-Silva
922 (irfernandez@uvigo.es), Loretta de Chiara (Ldechiara@uvigo.es), Pilar Gallego
923 (mgallego@alumnos.uvigo.es), Nair Varela (nvarela@alumnos.uvigo.es), Rosario Moreno
924 Muñoz (moreno_rosmuny@gva.es), M^a Dolores Tirado Balaguer (tirado_dolbal@gva.es), Ulises
925 Gómez-Pinedo (ulisesalfonso.gomez@salud.madrid.org), Mónica Gozalo Margüello
926 (monica.gozalo@scsalud.es), M^a Eliecer Cano García (meliecer.cano@scsalud.es), José Manuel
927 Méndez Legaza (josemanuel.mendez@scsalud.es), Jesús Rodríguez Lozano
928 (jesus.rodriguez@scsalud.es), María Siller Ruiz (maria.siller@scsalud.es), Daniel Pablo Marcos
929 (daniel.pablo@scsalud.es), Antonio Oliver (antonio.oliver@ssib.es), Jordi Reina
930 (jorge.reina@ssib.es), Carla López-Causapé (carla.lopez@ssib.es), Andrés Canut Blasco
931 (andres.canutblasco@osakidetza.eus), Silvia Hernáez Crespo
932 (silvia.hernaezcrespo@osakidetza.eus), M^a Luz Cordon Rodríguez
933 (marialuzalbina.cordonrodriguez@osakidetza.eus), M^a Concepción Lecaroz Agara
934 (mariaconcepcion.lecarozagara@osakidetza.eus), Carmen Gómez González
935 (carmen.gomezgonzalez@osakidetza.eus), Amaia Aguirre Quiñonero
936 (amaia.aguirrequiñonero@osakidetza.eus), José Israel López Mirones

937 (joseisrael.lopezmirones@osakidetza.eus), Marina Fernández Torres

938 (marina.fernandeztorres@osakidetza.eus), M^a Rosario Almela Ferrer

939 (mariadelrosario.almelaerrer@osakidetza.eus), José Antonio Lepe Jiménez

940 (josea.lepe.sspa@juntadeandalucia.es), Verónica González Galán

941 (veronica.gonzalez.galan.sspa@juntadeandalucia.es), Ángel Rodríguez Villodres

942 (angel.rodriguez.villodres.sspa@juntadeandalucia.es), Nieves Gonzalo Jiménez

943 (gonzalo_nie@gva.es), M^a Montserrat Ruiz García (ruiz_mongar@gva.es), Antonio Galiana

944 Cabrera (antoniogaliana1@gmail.com), Judith Sánchez-Almendro (judhsa@gmail.com), Gustavo

945 Cilla Eguiluz (CARLOSGUSTAVOSANTIAGO.CILLAEGUILUZ@osakidetza.eus), Milagrosa Montes

946 Ros (MARIAMILAGROSA.MONTESROS@osakidetza.eus), Luis Piñeiro Vázquez

947 (LUISDARIO.PINEIROVAZQUEZ@osakidetza.eus), Ane Sorrain

948 (ane.sorarrain@biodonostia.org), José María Marimón Ortiz de Zarate

949 (JOSEMARIA.MARIMONORTIZDEZ@osakidetza.eus), M^a Dolores Gómez Ruiz,

950 (gomez.mdo@gmail.com), Eva González Barberá (gonzalez_evabar@gva.es), José Luis López

951 Hontangas (lopez_jlu@gva.es), José María Navarro-Marí

952 (josem.navarro.sspa@juntadeandalucia.es), Irene Pedrosa Corral

953 (irene.pedrosa.sspa@juntadeandalucia.es), Sara Sanbonmatsu Gámez

954 (saral.sanbonmatsu.sspa@juntadeandalucia.es), M. Carmen Perez Gonzalez

955 (mcpergon@gobiernodecanarias.org), Francisco Javier Chamizo López

956 (fchalop@gobiernodecanarias.org), Ana Bordes Benítez (aborben@gobiernodecanarias.org),

957 David Navarro Ortega (david.navarro@uv.es), Eliseo Albert Vicent (eliseo.al.vi@gmail.com),

958 Ignacio Torres (nachotfink@gmail.com), M^a Isabel Gascón Ros (gascon_isa@gva.es), Cristina

959 Torregrosa Hetland (cjtoregrosahetland@hotmail.com), Eva Pastor Boix (pastor_eva@gva.es),

960 Paloma Cascales Ramos (cascales_pal@gva.es), Begoña Fuster Escrivá

961 (begona.fuster@gmail.com), Concepción Gimeno Cardona (concepcion.gimeno@uv.es), María

962 Dolores Ocete Mochón (ocete_mar@gva.es), Rafael Medina González

963 (rafa.medina.gonzalez@gmail.com), Julia González Cantó (juliagonzalez1992@hotmail.com),
964 Olalla Martínez Macias (martinez_ola@gva.es), Begoña Palop Borrás (bpalop@hotmail.com),
965 Inmaculada de Toro Peinado (inmadetoro@yahoo.es), M^a Concepción Mediavilla Gradolph
966 (gradolphilla@hotmail.com), Mercedes Pérez Ruiz
967 (mercedes.perez.ruiz.sspa@juntadeandalucia.es), Oscar González-Recio
968 (gonzalez.oscar@inia.es), Mónica Gutiérrez-Rivas (mgrivas9@gmail.com), Encarnación Simarro
969 Córdoba (mesimarro@sescam.jccm.es), Julia Lozano Serra (jlozanos@sescam.jccm.es), Lorena
970 Robles Fonseca (lrobles@sescam.jccm.es), Adolfo de Salazar (adolsalazar@gmail.com), Laura
971 Viñuela (lauravinuelagon@gmail.com), Natalia Chueca (naisses@yahoo.es), Federico García
972 (fegarcia@ugr.es), Cristina Gomez-Camarasa (gomezcamarasa@gmail.com), Ana Carvajal
973 (ana.carvajal@unileon.es), Vicente Martín (vicente.martin@unileon.es), Juan Fregeneda
974 (juan.fregeneda@unileon.es), Antonio J. Molina (ajmolt@unileon.es), Héctor Arguello
975 (hector.arguello@unileon.es), Tania Fernandez-Villa (tferv@unileon.es), Amparo Farga Martí
976 (farga_amp@gva.es), Rocío Falcón (falcon_roc@gva.es), Victoria Domínguez Márquez
977 (m.victoria.dominguez@uv.es), José Javier Costa Alcalde (jose.javier.costa.alcalde@sergas.es),
978 Rocío Trastoy Pena (rocio.trastoy.pena@sergas.es), Gema Barbeito Castiñeiras
979 (gema.barbeito.castineiras@sergas.es), Amparo Coira Nieto (amparo.coira.nieto@sergas.es),
980 María Luisa Pérez del Molino Bernal (maria.luisa.perez.del.molino.bernal@sergas.es), Antonio
981 Aguilera (antonio.aguilera.guirao@sergas.es), Anna M. Planas (anna.planas@iibb.csic.es), Álex
982 Soriano (asoriano@clinic.cat), Israel Fernández-Cádenas (israelcadenas@yahoo.es), Jordi Pérez-
983 Tur (jpereztur@ibv.csic.es), M^a Ángeles Marcos Maeso (mmarcos@clinic.cat), Carmen Ezpeleta
984 Baquedano (cezpeleb@navarra.es), Ana Navascués Ortega (ana.navascues.ortega@navarra.es),
985 Ana Miqueleiz Zapatero (ana.miqueleiz.zapatero@navarra.es), Manuel Segovia Hernández
986 (msegovia@um.es), Antonio Moreno Docón (a.moreno@um.es), Esther Viedma Moreno
987 (ester.viedma@salud.madrid.org), Jesús Mingorance (jesus.mingorance@idipaz.es), Juan Carlos
988 Galán Montemayor (juancarlos.galan@salud.madrid.org), Iván Sanz Muñoz

989 (isanzm@saludcastillayleon.es), Diana Pérez San José (dianaperezsj@gmail.com), Maria Gil
990 Fortuño (gil_marfor@gva.es), Juan B. Bellido Blasco (bellido_jua@gva.es), Alberto Yagüe Muñoz
991 (yague_alb@gva.es), Noelia Henández Pérez (hernandez_noeper@gva.es), Helena Buj Jordá
992 (helenitabuj@hotmail.com), Óscar Pérez Olaso (perez_oscola@gva.es), Alejandro González
993 Praetorius (agonzalezp@sescam.jccm.es), Aida Esperanza Ramírez Marinero
994 (aramirezm@lrc.cat), Eduardo Padilla León (epadillal@lrc.cat), Alba Vilas Basil (avilasb@lrc.cat),
995 Mireia Canal Aranda (mcanala@lrc.cat), Albert Bernet Sánchez (abernet.lleida.ics@gencat.cat),
996 Alba Bellés Bellés (abelles.lleida.ics@gencat.cat), Eric López González
997 (elopezg.lleida.ics@gencat.cat), Iván Prats Sánchez (iprats@gss.cat), Mercè García González
998 (mgarciag.lleida.ics@gencat.cat), Miguel Martínez Lirola
999 (miguelj.martinez.lirola.sspa@juntadeandalucia.es), Maripaz Ventero Martín
1000 (ventero_marmar@gva.es), Carmen Molina Pardines (molina_carpar@gva.es), Nieves Orta Mira
1001 (orta_nie@gva.es), María Navarro Cots (navarro_dia@gva.es), Inmaculada Vidal Catalá
1002 (vidal_inm@gva.es), Isabel García Nava (garcianava@hotmail.com), Soledad Illescas Fernández-
1003 Bermejo (msillescasf@sescam.jccm.es), José Martínez-Alarcón (jmalarcon@sescam.jccm.es),
1004 Marta Torres-Narbona (mtorresn@sescam.jccm.es), Cristina Colmenarejo
1005 (ccolmenarejo@sescam.jccm.es), Lidia García-Agudo (lgagudo@sescam.jccm.es), Jorge Alfredo
1006 Pérez García (jorgep@sescam.jccm.es), Martín Yago López (yago_mar@gva.es), María Ángeles
1007 Goberna Bravo (mariangoberna@gmail.com), Carolina Pla Cortes (caly.cortes@gmail.com),
1008 Noelia Lozano Rodríguez (lozano_noe@gva.es), Nieves Aparici Valero (aparici_nie@gva.es),
1009 Sandra Moreno Marro (moreno_sanmar@gva.es), Agustín Irazo Tatay (iranzo_agu@gva.es),
1010 Isabel Mariscal Pieper (mariscal_isa@gva.es), M^a Pilar Ramos (ramos_marrei@gva.es), Mónica
1011 Parra Grande (parra_mongra@gva.es), Bárbara Gómez Alonso (gomez_baralo@gva.es),
1012 Francisco José Arjona Zaragoza (arjona_fra@gva.es), Amparo Broseta Tamarit
1013 (amparo2400@gmail.com), Juan José Badiola Díez (badiola@unizar.es), Alicia Otero García
1014 (aliciaogar@unizar.es), Eloísa Sevilla Romeo (esevillr@unizar.es), Belén Marín González

1015 (belenm@unizar.es), Mirta García Martínez (gmmirta@hotmail.com), Marina Betancor Caro
1016 (mbetancorcaro@gmail.com), Diego Sola Fraca (diegosola95@gmail.com), Sonia Pérez Lázaro
1017 (soniperez97@gmail.com), Eva Monleón Moscardó (emonleon@unizar.es), Marta Monzón
1018 Garcés (mmonzon@unizar.es), Cristina Acín Tresaco (crisacin@unizar.es), Rosa Bolea Bailo
1019 (rbolea@unizar.es), Bernardino Moreno Burgos (bmoreno@unizar.es), Amparo Broseta Tamarit
1020 (abroseta@hospitalmanises.es), Carlos Gulin Blanco (cgulin@hospitalmanises.es)

1021 **Supplementary Material**

1022 **Supplementary video 1.** Geographical transmission of B.1.177.637 visualized with Nextstrain
1023 build.

1024 **Supplementary Tables**

1025 **Supplementary table 1.** Accession numbers for analysed sarbecoviruses.

1026 **Supplementary table 2.** Defining SNPs for B.1.177.637, B.1.177.637.V2, and VOI1163.654.

1027 **Supplementary table 3.** Accession numbers of sequences of interest for mutated amino acids
1028 484, 501, 1163 and 1167 of the S protein.

1029 **Supplementary table 4.** Accession numbers of 5,017 Spanish sequences from SeqCOVID-SPAIN
1030 consortium.

1031 **Supplementary table 5.** Accession numbers of 270,869 analysed sequences.

1032 **Supplementary table 6.** Accession numbers of 10,450 analysed sequences.

1033 **Supplementary table 7.** Accession numbers of 3,067 analysed sequences belonging to
1034 20I/501Y.V1.

1035 **Supplementary table 8.** Primers for site directed mutagenesis of plasmid encoding codon-
1036 optimized S protein.

1037 **Supplementary table 9.** Primers for sanger sequencing to detect mutations of interest.

1038 **Supplementary Figures**

1039 **Supplementary Figure 1. Temporal distribution of mutated samples coloured by region. a.**
1040 Distribution of S protein amino acid replacement D1163Y over the pandemic (N=1874). **b.**
1041 Distribution of S protein amino acid replacement G1167V over time (N=1708).

1042 **Supplementary Figure 2. Maximum-likelihood phylogenies for different PANGO lineages. a.**
1043 Complete phylogeny coloured by the PANGO lineages. **b.** Phylogeny of B.53 lineage. The circle
1044 represents sequences with D1163 amino acid replacement. **c.** Phylogeny of B.53 lineage. The
1045 inner circle represents sequences with D1163 amino acid replacements, and the external circle
1046 represents sequences with G1167 amino acid replacements. **d.** Phylogeny of A lineage. The circle
1047 represents sequences with D1163 amino acid replacements. **e.** Phylogeny of B.1 and derived
1048 lineages. The inner circle represents sequences with D1163 amino acid replacements, and the
1049 external circle represents sequences with G1167 amino acid replacements. **f.** Phylogeny of B.1.1
1050 and derivative D.1 lineages. The inner circle represents sequences with D1163 amino acid
1051 replacements, and the external circle represents sequences with G1167 amino acid
1052 replacements. **g.** Phylogeny of B.1.177 and B.1.177.637 lineages. The inner circle represents
1053 sequences with D1163 amino acid replacements, and the external circle represents sequences
1054 with G1167 amino acid replacements. The scale bar of each indicates the number of nucleotide
1055 substitutions per site. The legend of positions 1163 and 1167 is common for all represented
1056 panels.



1057 **Supplementary Figure 3. Whole genome mutated positions in genotypes with changes 1163Y**
1058 **and 1167V of the S protein.** B.1.177.637 is coloured in magenta and cluster 1163.654 is coloured

1059 in orange. Other less frequent genotypes (found in at least 20 sequences) that include changes
1060 in S position 1163 and/or 1167 are coloured in turquoise. Cluster 1163.654 is coloured in navy
1061 blue. Line width is proportional to the frequency of the genotype. Sites 1163 and 1167 in the S
1062 protein are indicated by magenta star symbols, and position 484 in S, whose mutations are
1063 associated with antigenicity changes, is indicated by a navy blue star.


1064 **Supplementary Figure 4. Maximum-likelihood phylogeny of 3,067 genomes belonging to**
1065 **20I/501Y.V1, rooted with Wuhan reference sequence.** Mutated sequences with 1163 and/or
1066 1167 amino acids of the S protein are coloured in the circle. The scale bar indicates the number
1067 of nucleotide substitutions per site. The biggest clades are collapsed with isosceles triangles.

1068 **Supplementary Figure 5. Maximum-likelihood phylogeny of 3,266 SARS-CoV-2 genomes**
1069 **representing 20E clade rooted with Wuhan reference sequence.** Sequences from B.1.177.637
1070 are coloured in magenta, sequences not identified as B.1.177.637 are coloured in green, and
1071 cluster B.1.177.637.V2 (S protein amino acid replacements: A222V, D614G, E484K, D1163Y, and
1072 141-144Del) is coloured in blue. The scale bar indicates the number of nucleotide substitutions
1073 per site. The biggest clades are collapsed, represented as isosceles triangles.


1074 **Supplementary Figure 6. Neutralization of the different mutated S protein variants by**
1075 **convalescent sera from six individuals infected during the first epidemic wave.** The reciprocal
1076 titer at which each of the different convalescent sera neutralizes the different variants by 50%
1077 is indicated. Plotted are the mean and standard error of (n=3).

a**b**


c




d




b




a



e





g




Position D1163	Position G1167
1163A	1167A
1163E/D	1167C/G
1163G	1167D
1163H	1167F
1163Y/D	1167R
1163H/Y/D	1167R/G
1163N/D	1167S
1163V	1167S/G
1163Y	1167V
	1167V/G

f








Sequences involving N501Y

- D1163A
- D1163N
- D1163V
- D1163Y
- G1167R
- G1167V
- D1163Y and G1167V

Tree scale: 0.001







20E




VOI1163.7





Tree scale: 0.0001













a**b****c**